LG00034053

LG00034053 is a novel small molecule caspase inhibitor developed by LG Chem for the treatment of osteoarthritis, particularly knee osteoarthritis. It is administered as an intra-articular injection and represents the world's first injection-type drug designed to block inflammatory pathways and inhibit chondrocyte (cartilage cell) apoptosis. By targeting caspases—key mediators of inflammation and cell death—LG00034053 aims not only to relieve pain but also to prevent cartilage damage, addressing both symptoms and disease progression in osteoarthritis. Preclinical studies demonstrated prolonged pain relief with a single administration and improvement in cartilage integrity. The drug has completed Phase 1b/2 clinical trials in Korea and Australia for knee osteoarthritis, with plans for global Phase 3 trials prior to commercialization[1][2][3][4][6].